Drug Trial Radar · NCT04895241
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
548
Actual
Start
May 25, 2021
Primary completion
Sep 30, 2026
Study completion Mar 16, 2027
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- May 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: \- How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), the British Isles Lupus Activity Group-2004 index (BILAG-2004), and the BILAG-BASED Combined Lupus Assessment (BICLA), among others. Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.
Conditions
- Lupus Erythematosus, Systemic
Interventions
LitifilimabDrug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52Time frame: Week 52
Locations
164 sites in 15 countries. Site status is shown where the registry gives one.
Tilda Research Birmingham
Homewood, Alabama
Wallace Rheumatic Study Center
Beverly Hills, California
University of Southern California
Los Angeles, California
Providence Facey Medical Foundation
Mission Hills, California
University of California San Diego School of Medicine
San Diego, California
SCLA Management
Thousand Oaks, California
Harbor-UCLA Medical Center
Torrance, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Georgetown University Hospital-Medstar
Washington D.C., District of Columbia
Arthritis & Rheumatic Disease Specialties
Aventura, Florida
Highlands Rheumatology
Avon Park, Florida
Clinical Research of West Florida - Corporate
Clearwater, Florida
Believe Clinical Trials
Coral Springs, Florida
Omega Research Consultants
DeBary, Florida
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida
GNP Research at Mark Jaffe, MD
Hollywood, Florida
Life Clinical Trials
Margate, Florida
Charisma Medical and Research Center
Miami Lakes, Florida
Rheumatology Associates of Central Florida
Orlando, Florida
AdventHealth Medical Group
Tampa, Florida
Vantage Clinical Trials
Tampa, Florida
Rheumatology care of Georgia
Kennesaw, Georgia
Atlanta Research Center for Rheumatology LLC
Marietta, Georgia
Accurate Clinical Research Inc.
Lake Charles, Louisiana
AA MRC LLC Ahmed Arif Medical Research Center
Flint, Michigan
Washington University School of Medicine
St Louis, Missouri
Renown Medical Group
Reno, Nevada
Joseph S. and Diane H. Steinberg Ambulatory Care Center
Brooklyn, New York
Northwell Health Center for Advanced Medicine
New Hyde Park, New York
University of Rochester Medical Center
Rochester, New York
SUNY Upstate Medical Center
Syracuse, New York
Joint and Muscle Research Institute
Charlotte, North Carolina
Medication Management, LLC
Greensboro, North Carolina
OnSite Clinical Solutions, LLC - Charlotte
Salisbury, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio
Hightower Clinical
Oklahoma City, Oklahoma
Ramesh C Gupta, MD
Memphis, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.